Dimerix Limited (SBMJF)
OTCMKTS · Delayed Price · Currency is USD
0.3500
+0.1000 (40.00%)
At close: Jun 4, 2025
Dimerix Revenue
In the fiscal year ending June 30, 2025, Dimerix had annual revenue of 5.59M AUD with 1,271.12% growth. Dimerix had revenue of 5.30M in the half year ending June 30, 2025, with 14,305.57% growth.
Revenue
5.59M AUD
Revenue Growth
+1,271.12%
P/S Ratio
58.00
Revenue / Employee
n/a
Employees
n/a
Market Cap
212.45M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2025 | 5.59M | 5.18M | 1,271.12% |
Jun 30, 2024 | 407.47K | 370.68K | 1,007.64% |
Jun 30, 2023 | 36.79K | -6.43M | -99.43% |
Jun 30, 2022 | 6.46M | 2.02M | 45.58% |
Jun 30, 2021 | 4.44M | 2.10M | 89.65% |
Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Tian'an Technology Group | 2.12M |
Veradigm | 588.02M |
Elite Pharmaceuticals | 105.45M |
Glass House Brands | 221.55M |
Northwest Biotherapeutics | 1.09M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
AMJ Global Technology | 39.00 |